

## DAFTAR PUSTAKA

1. Isbagio Harry, Albar Zuljasri, Yoga, Bambang. Lupus Eritematosus Sistemik. Dalam Sudoyo Aru, dkk (Eds). Buku Ajar Ilmu Penyakit Dalam. Balai Penerbit FK UI Jakarta; 2006;p.1214.
2. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. *Lupus*. 2006;15(5):308-18
3. Pusat Data dan Informasi Kementerian Kesehatan RI. Situasi Lupus di Indonesia. InfoDATIN; Jakarta. 2017
4. Bajwa A and Foster SC, Ocular Manifestations of Systemic Lupus Erythematosus, *J Clin Cell Immunol* 2014;5:1
5. Shoughy SS, Tabbara KF. Ocular findings in systemic lupus erythematosus. *Saudi J Ophthalmol*. 2016 Apr-Jun;30(2):117-21.
6. Ryan, S.J. Retina. Section 5 Chapter 75: Rheumatic Disease. British: Mosby Inc. 2006; p1390-94.
7. Hussein DA, El Bakry SA, Morshedy NA, Ibrahim SE, Mohammed MA. Ocular manifestations in Egyptian systemic lupus erythematosus patients and their relation with disease activity and anti-phospholipid antibodies. *The Egyptian Rheumatologist*. 2018;40(3):179-82.
8. Ramage AE, Fox PT, Brey RL, Narayana S, Cykowski MD, Naqibuddin M, et al. Neuroimaging evidence of white matter inflammation in newly diagnosed systemic lupus erythematosus. *Arthritis Rheum*.2011;63:3048–57.
9. Liu GY, Utset TO, Bernard JT. Retinal nerve fiber layer and macular thinning in systemic lupus erythematosus: an optical coherence tomography study comparing SLE and neuropsychiatric SLE. *Lupus*. 2015;24:1169–76.
10. Tavares Ferreira J, Alves M, Dias-Santos A, Costa L, Santos BO, Cunha JP, et al. Retinal neurodegeneration in diabetic patients without diabetic retinopathy. *Investig Ophthalmol Vis Sci*. 2016;57:6455–60.
11. Karaca C, Karaca Z. Beyond hyperglycemia, evidence for retinal neurodegeneration in metabolic syndrome. *Investig Ophthalmol Vis Sci*. 2018;59:1360–7.
12. Rapuano CJ, Stout JT, McCannel CA. Systemic Drug-Induced Retinal Toxicity. *Retina and Vitreous: American Academy of Ophthalmology*. San-Francisco. 2020-2021. p:295-7
13. Ctori I, Huntjens B. Repeatability of foveal measurements using spectralis optical coherence tomography segmentation software. *PLoS ONE*. 2015;10:e0129005.
14. Toledo J, Sepulcre J, Salinas-Alaman A, García-Layana A, Murie-Fernandez M, Bejarano B, et al. Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis. *Mult Scler*. 2008;14:906–12.
15. Cunha JP, Proença R, Dias-Santos A, Almeida R, Águas H, Alves M, et al. OCT in Alzheimer's disease: thinning of the RNFL and superior hemiretina. *Graefes' Arch Clin Exp Ophthalmol*. 2017;255:1827–35.

16. Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A. Retinal nerve fiber layer thinning in Parkinson disease. *Vis Res.* 2004;44:2793–7.
17. Dias-Santos A et al. Neurodegeneration in systemic lupus erythematosus: Layer by layer retinal study using optical coherence tomography. *International Journal of Retina and Vitreous.* 2020;6(1).
18. Tierney LM, McPhee SJ, Papadakis MA. Current Medical Diagnosis and Treatment. Arthritis and Musculoskeletal disorder. United States:McGraw-Hill/Appleton & Lange. 2004;p.805-807.
19. Donnithorne KJ, Read RW, Lowe R, Weiser P, Cron RQ, Beukelman T. Retinal vasculitis in two pediatric patients with systemic lupus erythematosus: a case report. *Pediatric Rheumatology.* 2013;11(1):25.
20. Dipiro JT, Talbert RL, Yee GC, Matzake GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiologic Approach seventh edition. United States: McGraw Hill. 2008;p.1432-1438.
21. Abbas K A, Lichtmant A H, Pillai S. Cellular and Molecular Immunology. Sixth ed. Philadelphia : W B Saunders Company; 2007.
22. Badawi AIZ, Abd El Hamid AM, Mohamed NK, Darwish EMM, Wassef M, Elfirgani H. Serum tumor necrosis factor (TNF) –like weak inducer of apoptosis (TWEAK) and leptin as biomarkers of accelerated atherosclerosis inpatients with systemic lupus erythematosus and antiphospholipid syndrome. *Egypt Rheumatologist* 2017;39(2):75–81.
23. De Groot PG, Derksen RHW. Patophysiology of the antiphospho lipid syndrome. *J Thromb Haemost* 2005;3:1854-60.
24. Ruiz SP, Cohen H, Isenberg D. The Pathophysiology of Antiphospholipid Syndrome. In *The Open Urology & Nephrology Journal.* 2015;8:2-9
25. Sivaraj, R.R., Durrani, D.M., Denniston, A.K., Murray, P.I., Gordon, C. Ocular manifestations of systemic lupus erythematosus. *Rheumatolog*, 2007;(46)12.p: 1757-1762
26. Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. *New England Journal of Medicine.* 2018 May 24;378(21):2010-21.
27. Kyttaris VC. Systemic lupus erythematosus: from genes to organ damage. *Methods Mol Biol.* 2010;662:265-83
28. Lahita RG. The clinical presentation of systemic lupus erythematosus. In: Lahita RG, Tsokos G, Buyon J, Koike T. Editors. *Systemic Lupus erythematosus*, 5th ed. San Diego. Elsevier; 2011: 525-540
29. Cojocar M, Cojocar IM, Silosi I, Vrabie CD. Manifestations of systemic lupus erythematosus. *Maedica (Bucur).* 2011 Oct;6(4):330-6. PMID: 22879850; PMCID: PMC3391953.
30. Karuniawaty TP, Sumadiono S, Satria CD. Perbandingan diagnosis systemic lupus erythematosus menggunakan kriteria American College of Rheumatologi dan Systemic Lupus International Collaborating Clinics. 2017;18(4):299-303.
31. Anic F, Zuvic-Butorac M, Stimac D, Novak S. New classification criteria for systematic lupus erythematosus correlate with disease activity. *Croat Med J* 2014;55:514-9.
32. Yu Cong, Gershwin ME, Chang C. Diagnostic criteria for systemic lupus erythematosus: A critical review. *J Autoimmun* 2014;48:10-3.
33. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R

- et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. *Arthritis Rheumatol.* 2019 Sep;71(9):1400-1412. doi: 10.1002/art.40930
34. Vellore C, Jacob M, Amith B. SLICC CLASSIFICATION CRITERIA FOR LES, 2015.
  35. Fauci AS. Systemic Lupus Erythematosus. In *Harrison's Principle of Internal Medicine 17<sup>th</sup> Edition*; 2018; Volume 2; page 1922- 1928.
  36. Lehman TJA. Systemic lupus erythematosus in childhood and adolescence. In *Lupus Erythematosus*. Edisi ke-7. Philadelphia: Lippincott Williams and Wilkins;2007;p. 848-66.
  37. Tolba DA, El Fayoumi DM, Abdel aziz MS, Nabih MH. Fluorescein angiographic findings in patients with active systemic lupus erythematosus. *Ocular Immunol Inflamm* 2016.
  38. Stavrou P, Murray P I, Batta K, et al. Acute ocular ischaemia and orbital inflammation associated with systemic lupus erythematosus. *Br J Ophthalmol.* 2002;86:474–5.
  39. Zink J M, Singh-Parikshak R, Johnson CS, et al. Hypopyon uveitis associated with systemic lupus erythematosus and anti phospholipid antibody syndrome. *Graefes Arch Clin Exp Ophthalmol.*2005;243:386–8.
  40. Wong R, Cunningham E. Posterior segment findings in LES. *Rev Ophthalmol.* 2013;20:41-5.
  41. Kumar K, Dan S, Sinha TK, Bhattacharya D. Severe Vaso-Occlusive Retinopathy in Systemic Lupus Erythematosus: A Case Series. *Cureus.* 2021 Jan 30;13(1):e13019.
  42. Fouad EA, Hanane M, Mounir B, Rachid Z, Karim RA. Severe Ischemic Retinopathy in a Patient with Systemic Lupus Erythematosus without Antiphospholipid syndrome: A Case Report. *Saudi Journal of Ophthalmology.* 2015;Vol 29:p.169-171.
  43. Shulman S, Shorer R, Wollman J, Dotan G, Paran D. Retinal nerve fiber layer thickness and neuropsychiatric manifestations in systemic lupus erythematosus. *Lupus.* 2017;26:1420–5.
  44. Nag T, Wadhwa S. Vascular changes of the retina and choroid in systemic lupus erythematosus: pathology and pathogenesis. *Curr Neurovasc Res.* 2006;3:159–68.
  45. Altinkaynak H, Duru N, Uysal BS, Erten Ş, Kürkcüoğlu PZ, Yüksel N, et al. Choroidal thickness in patients with systemic lupus erythematosus analyzed by spectral-domain optical coherence tomography. *Ocul Immunol Inflamm.* 2015. <https://doi.org/10.3109/09273948.2015.1006790>.
  46. Sankowski R, Mader S, Valdés-Ferrer SI. Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. *Front Cell Neurosci.* 2015;9:28. <https://doi.org/10.3389/fncel.2015.00028>.
  47. Cao X, Bishop RJ, Forooghian F, Cho Y, Fariss RN, Chan C-C. Autoimmune retinopathy in systemic lupus erythematosus: histopathologic features. *Open Ophthalmol J.* 2009;3:20–5.
  48. McCannel CA et al. Diagnostic Approach to Retinal Disease. In *American Academy of Ophthalmology Retina and Vitreous*. USA: American Academy of Ophthalmology.2021-2022;p.21-39

49. Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. *JCI insight*. 2017; 20:2(14).
50. Schubert HD. Structure of the Neural Retina. In: *Ophthalmology*. 5th ed. Philadelphia, PA. 2019; p.419-422.
51. Skalicky SE. *Ocular and Visual Physiology*. Sydney: Springer; 2016;p.285–298
52. Gregg RG, Singer J, Kamermans M, McCall MA, Massey SC. Function and Anatomy of the Mammalian Retina. In *Ryan's Retina*. Edisi ke-6. China: Elsevier; 2018;p.360-400
53. Filho CA, Yehoshua Z, Gregori G, Puliafito CA, Rosenfeld PJ. Optical Coherence Tomography. In *OCT of ocular diseases*. In *Ryan's Retina*. Edisi ke-6. China: Elsevier; 2018;p.82-109
54. Hegazy AI, Zedan RH, Macky TA, Esmat SM. Retinal ganglion cell complex changes using spectral domain optical coherence tomography in diabetic patients without retinopathy. *Int J Ophthalmol*. 2017 Mar 18;10(3):427–33.
55. Tian J, Zhang D, Yao X, *et al*. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study *Annals of the Rheumatic Diseases* 2023;**82**:351-356.
56. Izzati SA. Hubungan Antara Aktivitas Lupus Eritematosus Sistemik (LES) dengan Manifestasi Segmen Posterior pada Mata. Universitas Brawijaya (thesis). 2020
57. Seth G, Chengappa K, Misra DP, Babu R, Belani P, Shanoj K, Kumar G, Negi VS. Lupus retinopathy: a marker of active systemic lupus erythematosus. *Rheumatol Int*. 2018;38(8):1495–1501.
58. Pelegrín L *et al*. Preclinical ocular changes in systemic lupus erythematosus patients by optical coherence tomography. *Rheumatology (Oxford)*. 2023 Jul 5;62(7):2475-2482.
59. Jones BW, Pfeiffer RL, Ferrell WD, Watt CB, Marmor M, Marc RE. Retinal remodeling in human retinitis pigmentosa. *Exp Eye Res*. 2016;150:149–65.